Loading ...FDA Approves First RSV Vaccine, But Some Experts Say Weak Safety, Efficacy Data Suggest Benefits Don’t Outweigh Risks
The U.S. Food and Drug Administration on Wednesday approved Arexvy, the first vaccine for respiratory syncytial virus, amid concerns among some experts that the vaccines aren’t worth the risks.
Describing it as a “long-sought scientific achievement,” the U.S. Food and Drug Administration (FDA) on Wednesday approved Arexvy, the first vaccine for respiratory syncytial virus (RSV).
GlaxoSmithKline Biologicals (GSK) developed Arexvy under the FDA’s Priority Review designation. The FDA approved it for people ages 60 and older.
https://childrenshealthdefense.org/defender/fda-approves-rsv-vaccine-arexvy/?
some experts that the vaccines aren’t worth the risks.
You need to be an “expert?” to know this ?
Next time I need medical help, I’m going to the witch doctor. Better odds, I figure!